$250.00
Tirzepatide, a synthetic derivative of gastric inhibitory polypeptide (GIP), exhibits simultaneous glucagon-like peptide-1 (GLP-1) functionality, making it a versatile compound for research. Initially developed to combat type 2 diabetes, Tirzepatide has shown additional benefits in protecting the cardiovascular system and acting as a potent weight loss agent. Research indicates that Tirzepatide can lower blood glucose levels, increase insulin sensitivity, enhance feelings of satiety, and accelerate weight loss. Ideal for research applications, Tirzepatide offers a promising tool for exploring advanced therapeutic strategies in diabetes management, cardiovascular health, and obesity treatment.
Tirzepatide 10mg may have a greater effect than strict GLP-1R agonists since it may show synergistic agonistic potential on the GLP-1 and GIP receptors. According to research, tirzepatide 10mg may have a higher affinity for GIP-R than GLP-1R. The small intestine naturally produces GIP or glucose-dependent insulinotropic polypeptide. Insulin is released when binding to GIP-R occurs; however, gastrin and acid secretion are inhibited. The brain’s beta cells and neurons contain GLP-1R, and activating it increases insulin synthesis and release, decreasing appetite. Furthermore, through improving bcl-2 gene expression and lowering apoptosis, GLP-1R activation raises beta cell density in the pancreas and ultimately raises insulin levels. (3)
According to research, tirzepatide 10mg may function at GIP-R exactly like GIP does, but at GLP-1R, it seems to prioritize cAMP synthesis over β-arrestin recruitment. Tirzepatide has the potential to be more effective than other synthetic GLP-1R agonists because of its distinct action from endogenous GLP-1, which results in increased GLP-1R activity without increasing the physiological internalization of the receptor. Tirzepatide decreases inflammation in adipose tissue, increases sensations of fullness, and may stimulate insulin release.
Moreover, tirzepatide may alter adiponectin levels, raising total amounts of this peptide that burns fat, decreasing the differentiation of fat cells, and raising energy expenditure. Type 2 diabetes, non-alcoholic fatty liver, and atherosclerosis are all linked to low adiponectin levels. (4)
*The purpose of this product is solely for chemical research. Under this categorization, research compounds may only be used for in vitro testing and laboratory experiments. This website only provides product information for educational purposes. It is illegal for humans or animals to be introduced bodily parts of any kind. It is only appropriate for licensed and qualified specialists to handle this product. This product may not be mislabeled, abused, or mislabeled as a medication, food, or cosmetic because it is not one of those things.
At Gentera Med Peptides, pride in our craftsmanship is at the heart of everything we do. Our commitment to excellence and attention to detail ensure that every project we undertake meets the highest standards of quality and durability.
General Information: info@genteramed.com
Orders: gentera@peptide-fulfillment.com
Mon – Thurs / Excluding holidays
Orders placed and paid for after 12PM PST are shipped the following business day
550 Biltmore Way Suite 101,
Coral Gables, FL 33134
© 2024 Gentera Peptides, Inc. All Rights Reserved.
The statements made on this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure, or prevent any disease.
